The pharmacovigilance legislation of 2012 requires companies to provide Risk Management Plans (RMPs) and assessments for all new products, whether generic products or new chemical entities.
5 Jul 2018
& 29 Jan 2019
GBP 699 599 *
EUR 979 839 *
USD 1,090 934 *
* When you book before 9 May
The new pharmacovigilance legislation of 2012 now requires companies to provide a PSMF and that this document should be ‘Inspections ready’. If this is not done correctly this can result in critical findings for the Company that could set back further product launches or event sanctions against the Company existing products. Maintenance of the PSMF also is an important aspet for maintaining the Company compliance and these are reviewed in Regulatory Inspections. Can you afford not to get it right?
Topics to be covered Include:-
Please note that we are also running:
This meeting runs back-to-back with Writing Risk Management Plans (RMPs) on 4 July 2018 and also Risk Evaluation and Mitigation Strategies (REMS) on 6 July 2018. There is a further £100/€140 discount off each course when booked together.
To find out more please call Customer Services on +44 (0)20 7749 4730 or e-mail firstname.lastname@example.org
EU Regulatory Authorities are visiting all licence holders to perform inspections on a Company’s compliance to Pharmacovigilance and the visits start with the assessment of the PSMF. This document provides the Regulators with not only the detailed assessment of the system but also the outputs from that system contained in the Annexes to gain an understanding of the Company compliance. The new Pharmacovigilance Legislation of 2012 now requires companies to provide a PSMF and that this document should be ‘Inspection ready’. If this is not done correctly this can result in critical findings for the Company that could set back further product launches or even sanctions against the Companys existing products. Maintenance of the PSMF also is an important aspect for maintaining the Company compliance and these are reviewed in Regulatory Inspections. Can you afford not to get this right?
This course will be relevant for anyone requiring a comprehensive overview of the Pharmacovigilance function and duties. It may be of particular interest to those who are responsible in Pharmacovigilance for any safety assessments and writing such plans including any EU QP PVs who approve such documents. Those who work with pharmacovigilance, e.g. Regulatory Affairs, Clinical, Sales & Marketing, Legal, Commercial and Quality and IT that must sign off such documents.
An Introduction to PSMFs
The Content of the PSMF
The Sections of the PSMF
The Annexe requirements for the PSMF
Graeme Ladds (5 Jul 2018)
Graeme Ladds, Director of PharSafer, has over 26 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.